This is topic CLBE watch for volume increase !! rumors flying in forum Micro Penny Stocks, Penny Stocks $0.10 & Under at Allstocks.com's Bulletin Board.
get in before the week ends, expecting profitable quarterly!!
[ August 09, 2006, 14:48: Message edited by: Bob Frey ]
Posted by QuestSolver on :
watching for .08's or more soon now,expect news by Monday morning imo
Posted by QuestSolver on :
getting active.....very few shares left in the .05's imo
Posted by The Phat Man on :
what/where are the rumors quest? any elaboration on profitability? or anything further? thanks,
Posted by The Phat Man on :
volume kinda blows right now which is what's keeping me away for the moment. i do like this play's potential though. somewhat currently in the middle of the rise to a double neck / shoulder rebound. and, yes, thus .08 seems reasonable.
Posted by QuestSolver on :
the .055 area is the bottom....watch for the quarterly by Friday imo and the announcements of the banking on the 14th or 15th also imo.
Posted by QuestSolver on :
getting alerts from friends on the west coast that CLBE is ready to rock and roll...the past info supports that to and its due.
Posted by QuestSolver on :
I picked up a few more shares before I have to roll out for the day.....I feel quite confident in CalbaTech and the things they have in the works right now!! theres no way this stays under a dime much longer imo.
Posted by QuestSolver on :
trying to buy the last few at bid but will move it to the ask soon...any buys in the .05's will prove very profitable soon imo.
Posted by QuestSolver on :
Adult stem cell biotechs: better prospects, less controversy Several outfits are in the advanced stages of testing adult stem cells to help repair damaged bones as well as heart and breast tissue., By Aaron Smith, CNNMoney.com staff writer August 9 2006: 3:37 PM EDT
Posted by QuestSolver on :
CLBE is a definite buy and hold for bigger things near term
New York, NY (LifeNews.com) -- More financial analysts are saying that biotech firms that work with adult stem cell research are better prospects for investors than those working with embryonic stem cells. The news comes after lobbyists and lawmakers condemned President Bush for focusing federal taxpayer dollars on adult stem cell research. Last week, LifeNews.com reported on one investment advisor who said companies relying on adult stem cells are more likely to provide payoffs for investors. Other a nalysts say that adult stem cells companies like Osiris, Cytori, Aastrom should be monitored by investors for possible buys because they are more likely to get therapies on the market than companies using embryonic stem cells.
"From a Wall Street perspective, adult stem cells are a much better investment," Stephen Dunn of Dawson James Securities, told CNN. "These are the guys who are going to be in the news in 2007 and 2008."
"Embryonic stem cell research hasn't kept up pace with adult stem cell research," Dunn added. "Adult stem cell research is advancing so far you might not need embryonic stem cells. If the federal government is reluctant to put their money into it, then Wall Street is as well."
While embryonic stem cell research has seen numerous failures with animals and may be a decade or more away from producing any human therapies, adult stem cell research has already yielded dozens of treatments -- some of which may be at the market within years.
The Baltimore-based Osiris Therapeutics initially offered stock on August 4 and already has a product on the market called Osteocel that helps rebuild damaged bones.
The company would have advanced further in promoting the product, CNN reports, if not for having a hard time finding enough donors of bone tissue to build up its stem cell inventory.
Thus, while some politicians clamor for more taxpayer dollars for embryonic stem cell research that may never help patients, funds for obtaining more bone tissue would help patients today.
Osiris has another adult stem cell product, Prochymal, which helps patients with a life-threatening affliction called Acute Graft versus Host Disease. The same drug is also being tested for use in treating Crohn's disease.
Stephan Brozak, analyst for WBB Securities, told CNN he likes the product and reports he's seen show patients have experienced "remarkable results."
The company is in the final stages of clinical trials and will soon be ready to submit the drug to the FDA in 2007.
Dunn tells CNN he's bullish on another company, Michigan-based Aastrom Biosciences, which also develops an adult stem cell therapy dealing with regrowing bone tissue.
Meanwhile, the San Diego biotech Cytori Therapeutics uses adult stem cells from fat to rebuild damaged tissue. Via a liposuction technology called Celution, the company is taking the cells from a patient and reinserting them into the patient's body at the point of the problem.
The process is also being used to help improve heart function in patients with severe coronary artery disease. That could be sent to the FDA for approval in 2008 and the liposuction procedure could be sent to the FDA next year.
WBB Securities' Brozak says the FDA approval process for these new therapies may take longer because the science is newer, but he says these companies have a good shot at bringing the products to market.
Posted by QuestSolver on :
E&E just released this!!! had a feeling the PR's release were related to our puppy!!
LOL...look what E&E just put out for CLBE....I e-mailed Paul both the news reports you guys posted here!!
CalbaTech (OTC BB: CLBE): Why It Is Smart to Be Involved in Collection of Adult Stem Cells
More Financial Analysis Say Adult Stem Cell Research Companies Better
by Steven Ertelt LifeNews.com Editor August 9, 2006
New York, NY (LifeNews.com) -- More financial analysts are saying that biotech firms that work with adult stem cell research are better prospects for investors than those working with embryonic stem cells. The news comes after lobbyists and lawmakers condemned President Bush for focusing federal taxpayer dollars on adult stem cell research. Last week, LifeNews.com reported on one investment advisor who said companies relying on adult stem cells are more likely to provide payoffs for investors.
"From a Wall Street perspective, adult stem cells are a much better investment," Stephen Dunn of Dawson James Securities, told CNN. "These are the guys who are going to be in the news in 2007 and 2008."
"Adult stem cell research is advancing so far you might not need embryonic stem cells. If the federal government is reluctant to put their money into it, then Wall Street is as well." Dunn added.
While embryonic stem cell research has seen numerous failures with animals and may be a decade or more away from producing any human therapies, adult stem cell research has already yielded dozens of treatments -- some of which may be at the market within years.
The company is in the final stages of clinical trials and will soon be ready to submit the drug to the FDA in 2007.
*****
Adult stem cell biotechs: better prospects, less controversy Several outfits are in the advanced stages of testing adult stem cells to help repair damaged bones as well as heart and breast tissue., By Aaron Smith, CNNMoney.com staff writer August 9 2006: 3:37 PM EDT
NEW YORK (CNNMoney.com) -- Embryonic stem cells might hold the secrets to curing paralysis and brain damage, but they've also garnered plenty of controversy with the anti-abortion lobby because they're harvested from embryos.
However, work using adult stem cells - which are donated by grown men and women - is not only free of such controversy, it's actually much closer to getting effective products on the market.
Work with adult stem cells isn't being held back by funding restraints and political opposition, analysts say.
"Embryonic stem cell research hasn't kept up pace with adult stem cell research," said Dunn. "Adult stem cell research is advancing so far you might not need embryonic stem cells. If the federal government is reluctant to put their money into it, then Wall Street is as well."
So while embryonic stem cell researchers are experimenting with rats, adult stem cell researchers have moved on to more advanced tests with humans. The embryonic-based stem cell treatments are probably a decade away, but the U.S. market could see its first adult-based stem cell treatments within the next couple of years.
Posted by Werner on :
HUGE MOMENTUM BUILDING UP!!!!
Going in BIGTIME tomorrow morning. Once we see how good the 2nd QTR Financials are this is going to f'kn explode into the multi-pennies! .12 - .14 easily! The financials could be out any day now. No later than monday the 14th and as soon as TOMORROW!
BOOYAH!!!!
Posted by Werner on :
Is it just me or does it look like CLBE is forming a cup and handle on the chart? Looks like the handle is just finishing and the breakout is about to begin!
Posted by QuestSolver on :
CLBE: Launch Date 0f Aug 15th for Stem Cell Microbank
CalbaTech, Inc. (CLBE) announced that its wholly owned subsidiary, LifeStem, Inc. will begin operations of its Adult Stem Cell Microbank(TM) collection service on August 15th 2006.
Posted by QuestSolver on :
CLBE First Alert News Brought To You By:
8/10/06 8:10:55 AM *********.com: Price and Volume Alerts for Thursday August 10, 2006 - One Company Announces Launch Date for Stem Cell Microbank While Another Receives Vendor Setup and Fridge Tape(R) Purchase Order
Posted by QuestSolver on :
well heres what we have in the works....the stem cell banking will be underway on the 15th.....the expected positive financials can be released at anytime now....the MedSpa's will have 38 to 50 new locations opening before year end...the CEO made a clear statement that CalbaTech will be profitable in 2006....this is just some tidbits......everyone here by now should have at least a small position in CLBE or get in ASAP imo....this is not one to flip constantly.
Posted by QuestSolver on :
I have a AON tester sitting on the ask and not even getting anibble yet....just need more buying pressure and this will jump to .065 on just a few small buys imo.
Posted by Livinonklendathu on :
In yesterday and some more today - chart setting up great.
Posted by QuestSolver on :
.06 x .063 and volume increasing
Posted by Squire38 on :
I guess I sorta expected it to rise a bit faster. Either way green is good. I'll take 5% a day.
Posted by QuestSolver on :
looking strong on the bid side.
Posted by QuestSolver on :
they have a lot going on between today and next Tuesday so I expect a lot more green.
Posted by cali99boy on :
just jumped in this a few mins ago Posted by QuestSolver on :
bid is looking even better now guys and this should only get stronger over the next week.CLBE is definitely one to have a core position in in the long run.....I have no doubt that this will be trading much much higher before year end.
Posted by QuestSolver on :
lunchtime lull and holding strong.....nice.
Posted by QuestSolver on :
links to DD CLBE and see why we know this one is going to be a major holder and a major player in this sector
lunchtime ending soon....might get us into an EOD rally since we have so much going on the next few trading days!
Posted by QuestSolver on :
e-mail from Paul in response to my questions.
Quest Solver wrote:
Hi Paul....I was just wondering...when you send out an e-mail like this how many people does it reach? Is it also posted elsewhere as a PR or share holder info so that many in the public can see it?
TIA
Hank
We maintain two lists. One is for CalbaTech. Anyone who wants CalbaTech news releases, etc. is on that one. We also maintain a list of about 1,200 individuals, brokers, others who seem to have a taste for micro caps, who have had success with our clients, and who want this information. We send to them information when I think it particularly relevant. We assist circa 15 companies so I don't want to overwhelm anyone with everything. I hope this helps.
Paul Knopick
Posted by QuestSolver on :
feel free to contact IR and ask anything you want about this company......they definitely respond to share holders!
Paul Knopick <pknopick*eandecommunications.com>
Posted by QuestSolver on :
last OS numbers I got was just slightly over 125 mill.....the 10-q will be out anytime so we will know exactly soon.
Posted by nfsx2417 on :
.6 x .62 now
Posted by QuestSolver on :
.063
Posted by QuestSolver on :
Investors can take this to the bank: the promise and efficacy of stem cell therapies will ultimately trump the politics. The medical potential is simply too great to ease suffering, salvage patient lives and save the healthcare industry a massive slug of money. Not to mention throwing off some great investment opportunities. Over 70 companies --the vast majority of them small or microcaps-- are doing some amazing work on stem cell therapies.
We have recently unearthed a great smallcap biotech company that deals directly in this realm and plan to bring it to you in the next week or two. In the interim, it would be to your benefit to get to know the ins and outs of the stem cell landscape
Here’s a link to several other stem cell companies worldwide. http://www.stem-cell-companies.com/. Be advised, many are in their formative stages. Careful review is warranted. As in every new sector, not all will prosper or even survive.
Profits soon. Well, pretty soon.
Revenues from current stem cell initiatives should begin to bite in a meaningful way by 2009, exploding to almost $4 billion-plus by 2015. Beyond that, the sky is likely the limit. Investors who see the potential, now, will likely garner the best returns as the scenario unfolds.
Nearly $15 billion will be spent over the next decade on both embryonic and adult stem cell research/therapies. States, such as California, recently passed a contentious initiative (Proposition 71), which earmarks $3 billion --by way a pending bond issue-- over the next ten years for stem cell research. Other states are looking at California’s lead to acquire stem cell funding in an effort to make up the R&D shortfall that has resulted from limited federal participation.
On the threshold of greatness. And profits
We believe that investors are on the threshold of a whole new and extremely exciting genus of therapies. While acknowledging the controversy around this sector, the over-riding fact is that the formative science is just too compelling to ignore both for healthcare and especially those patients suffering debilitating disease.
Is it too early to consider stem cell investing? Would it have been too early to buy Microsoft years ago or to be an early investor with a young(er) Warren Buffett? That’s the type of long-term trend we believe is in the early process of unfolding for stem cell companies. For those investors who have the patience and risk tolerance, there will be some very exciting names coming forward, including those that we will illuminate for readers.
The Two Types of Stem Cells.
Stem cells differ from other kinds of cells in the body. All stem cells—regardless of their source—have three general properties: they are capable of dividing and renewing themselves for long periods; they are unspecialized; and they can give rise to specialized cell types.
Adult stem cells are thought to reside in a specific area of each tissue where they may remain quiescent (non-dividing) for many years until they are activated by disease or tissue injury. The adult tissues reported to contain stem cells include brain, bone marrow, peripheral blood, blood vessels, skeletal muscle, skin and liver.
Globally, scientists are trying to find ways to grow adult stem cells in cell cultures and manipulate them to generate specific cell types so they can be used to treat injury or disease. Some examples of potential treatments include replacing the dopamine-producing cells in the brains of Parkinson's patients, developing insulin-producing cells for type I diabetes and repairing damaged heart muscle following a heart attack with cardiac muscle cells.
Embryonic stem cells as their name suggests, are derived from embryos after about five days. Specifically, these stem cells are derived from embryos that develop from eggs that have been fertilized in vitro —in an in-vitro fertilization clinic—and then donated for research purposes with the informed consent of the donors.
the stem cell issue is constantly being looked at and debated and since there have been several variences of stem cell usage the banking system will have to be one part that will be constant since all the stems need to be secured.Once real successes start getting printed then you can bet that health insurance providers will be looking at individual stem cell banking to protect the insurance companies in the long run.Hell as stated here before it may end up being a requirement by the health insurance companies to secure policies....face it people this technology is not going away and is only going to be enhanced and refined.
Posted by banah18 on :
Im thinkin of adding some
Posted by banah18 on :
But doesnt look it can go high , 0.0830 ?
Posted by QuestSolver on :
it broke into the teens on less news and events not long ago and the numbers have not changed,they have a lot going on between today and Tuesday...positive 10-Q and the formal opening of the stem cell banking systems on the 15th
Posted by QuestSolver on :
August 11, 2006 Dallas, Texas, Aug 11, 2006 (M2 PRESSWIRE via COMTEX News Network) -- ********* Pre-Market Updates for Friday include Sure Trace Security Corporation (OTC: SSTY), CalbaTech Inc (OTCBB: CLBE), ProtoKinetix, Inc. (OTCBB: PKTX), Autoinfo Inc (OTCBB: AUTO), Earth Biofuels, Inc. (OTCBB: EBOF), and Composite Technology Corporation (OTCBB: CPTC) . ********* Pre-Market Updates feature companies with significant moves in either volume or price in the past two trading sessions. In our update we analyze recent news about the companies featured and detail the movement in the stock. If you would like to feature your publicly traded company in our alerts or on *********.com, email feature**********.com or call (469)252-3031.
CalbaTech Inc (OTCBB: CLBE) - Thursday's shares went up 1.67% to $0.061 with a total of 873,023 shares traded. On July 24, CalbaTech, Inc. announced that its wholly owned subsidiary, LifeStem, Inc. will begin operations of its Adult Stem Cell Microbank(TM) collection service on August 15th 2006. LifeStem's Stem Cell Microbank(TM) Service is the nation's first service to collect micro quantities of adult stem cells from multiple tissue sources. "We have completed the validation of our protocols to guarantee that our service will run smoothly at the time of launch," said James DeOlden, CEO. "LifeStem and its partners are now satisfied with the vitality and viability of the cells that have been collected." Additionally, CalbaTech, in coordination with LifeStem, announced that it will be offering a ten percent discount coupon for LifeStem's Stem Cell Microbank(TM) collection service, to shareholders of record as of August 10, 2006. The discount is available to the individual shareholder, or any member of the shareholder's immediate family at the shareholder's listed address.
CalbaTech, Inc., a life sciences company, provides products and platforms to the research market for biotech and pharmaceutical companies, as well as to academic institutions. Through its three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, as well as wholly owned subsidiaries, including Molecula, Inc.; KD Medical, Inc.; LifeStem, Inc.; and MolecularWare, Inc., the company is developing products and technologies in biological discovery. The Molecular Applications division has an active program of molecular biology applications and research, including pathogen microarrays, diagnostics, electronic-based DNA detection systems, and DNA sample preparation. The Research Reagents division provides cell and molecular biology reagents and related consumables. It develops and sells research reagents for cell transfection, DNA and RNA purification, protein expression, gene expression analysis, and other fundamental products. The Cellular Therapeutics division focuses on cellular applications, particularly those relating to the use of adult stem cells. It includes cell-based research projects for the delivery of cell-based clinical therapies. CalbaTech was founded in 2002 and is based in Irvine, California.
Posted by QuestSolver on :
really impressed so far with the way its looking....low volume and holding up well.....like to see some block buys before close for the upcoming week!
Posted by maxdog on :
I jumped in yesterday. However I see that MSDN had afterhours new also, do you think this will have any effect on us?
Posted by QuestSolver on :
the market is slow today for many stocks out here...even big board plays.
Posted by QuestSolver on :
quote:Originally posted by maxdog: I jumped in yesterday. However I see that MSDN had afterhours new also, do you think this will have any effect on us?
is that symbol right?
Posted by maxdog on :
Sorry, apparently can't type, that is MDSM
Posted by QuestSolver on :
quote:Originally posted by maxdog: Sorry, apparently can't type, that is MDSM
LOL....I have been there before...more then once...LOL
I think it will help put us in the spotlight since we and a few other companies are starting to get into this business and we open up on Tuesday.
Posted by QuestSolver on :
now you can see that CLBE is not the only company interested in this market!! and we got a head start...LOL
Medistem's International Affiliate ICM Granted License to Operate Adult Stem Cell Bank and Clinic; Opening of Pioneering Facility Represents Threshold Event in Medistem's Business Plan to Deliver Stem Cell Therapies Business Wire - August 10, 2006 4:01 PM ET
Medistem Laboratories, Inc. (OTCBB:MDSM)(FWB:S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, has announced that its affiliate, the Institute for Cellular Medicine (ICM), has received approval from the Costa Rican Health Ministry to begin operations of its adult stem cell bank and clinic.
With the state-of-the-art stem cell bank and clinic now open, ICM will begin working hand-in-hand with medical doctors in the treatment of patients with stem-cell therapies based on Medistem's proprietary technologies. The ICM lab will apply Medistem's proprietary adult stem cell technologies that can be sourced from umbilical cords, placentas, fat, bone marrow, and muscle.
The opening of the ICM bank and clinic represents a critical milestone in Medistem's primary business plan to develop and deliver pioneering stem cell treatments on a fee-for-service basis through its international affiliates at facilities worldwide. Under its strategic business plan, Medistem with its affiliates plans to create potentially valuable intellectual property in the field of stem cell medicine.
The ICM laboratory will be one of the first stem cell banks in Latin America to produce the adult stem cells necessary for the development of stem cell based medical treatments. "We are very excited to be able to use Medistem's stem cell technology to produce stem cells for use by the medical community," said Dr. Fabio Solano, Medical Director of ICM. "We believe their technology holds a great deal of promise in the creation of important therapeutic solutions for seriously debilitating diseases."
The stem cell bank and clinic will work with the medical community in the treatment of patients with stroke, cerebral palsy and other neurological disorders. ICM also intends to develop treatments for a range of other health care needs, including cardiovascular disease.
Under a licensing agreement with ICM, which is controlled by Medistem's Chief Executive Officer, Medistem granted a license to ICM to use certain of its intellectual property and agreed to fund all necessary operating expenses in exchange for certain revenues and gross profits involving both adult stem cells and non-stem cell based activities.
Posted by maxdog on :
It isn't doing much today, I anticipated it moving more on the new. But, as you said nothing is moving much.
Posted by QuestSolver on :
if CLBE gets any action on Fridays it usually after 2pm into close.
Posted by QuestSolver on :
don't be surprise to get a weekend PR on CLBE concerning Monday and Tuesday. A e-mail from IR just confirmed that another spa is right now in negotiation with Calbatech concerning stem cell therapy
Posted by QuestSolver on :
EOD action kicking in!!!! financials either after hours or Monday imo!!! banks opening Tuesday and are now in negotiations with another Spa company to!!
Posted by maxdog on :
Here is a new week with good things happening.
Posted by nfsx2417 on :
Hopefully this thing'll jump early next week
Posted by QuestSolver on :
Stem cell breakthrough in Japan KYOTO, Japan, Aug. 11 (UPI) -- Japanese researchers have been able to make adult cells act like embryonic stem cells, at least in mice.
Shinya Yamanaka of Kyoto University said he believes the technique could end the debate on the destruction of embryos to obtain embryonic stem cells, the Milwaukee Journal Sentinel reported. If it is as successful with human cells as it is with mice, early embryos or blastocytes would no longer be needed.
Yamanaka and his colleague Kazutoshi Takahashi found 24 genes that are expressed in early embryos. They found that a combination of four of these cells could make adult cells "pluripotent."
In other words, they became like embryonic stem cells and capable of differentiating into many kinds of cells.
In addition to bypassing the ethical dilemmas of embryonic stem cell research, the technique could solve the problem of rejection by allowing a patient's own cells to be used for treatment.
But Robert Lanza of Advanced Cell Technology, a Massachusetts biogenetics company, warned there are potential pitfalls. He told the Journal Sentinel one of the genes involved is associated with cancer and the genetic manipulation also makes cells more prone to become cancerous.
The research was published in the journal Cell.
Posted by QuestSolver on :
here is whats in the works for this week...
the stem cell banking system formally opens tomorrow on the 15th. we recieved info Friday that Calbatech is also in final negotiations with another Medspa company. The first Medspa company Solena will be opening 38 to 50 locations before year end and have already opened many so far. CLBE substantially owns a good portion of Solena and they are far more then just partners in this. CLBE will be profitable in 2006 per the CEO.....we expect the financials anytime now more then likely sometime today. Health care providers such as Blue Cross/Blue Shield will eventually require stem cell banking to qualify for insurance imo,that way they remove a lot of risk of long term health care issues per individual.IMO CLBE should be at or near .50'ish by year end but could go higher. I can see this hitting $2 to $4 within the next 12 to 18 months.The banking/theropy system is a double digit billion dollar market and growing and thats just one division of Calbatech.
Posted by QuestSolver on :
Check out that gapper for CLBE!!! and that rarely ever happens for this stock!!
Posted by QuestSolver on :
gradually moving up .063 x .064 and the best time for movement with CLBE is after 2:00!
Posted by Squire38 on :
Looks like today will be a good day. Not even 10 minutes into the day and volume is well above normal.
Posted by QuestSolver on :
I feel now that CalbaTech has the base set up and the ducks are all in a row (all the sub-divisions) that compliment each other....with the banking system opening tomorrow and other Spa's contacting CLBE this could get explosive.
Posted by QuestSolver on :
new HOD
Posted by QuestSolver on :
look at the buying increase at .065,I thru a tester out for 2825 shares and it took a while and in two partials....that tells me that buying blocks now is going to be very hard and even herder towards the end of the day imo.
Posted by JimSC on :
It's a small world. KD Medical buys petri dishes from FRANCE (Plastiques Gosselin, John Gosselin in green shirt) buys ploycarbonate 1L bottles from TAIWAN (TriForest Industries, Steve Lin in white shirt) and develops new products with Dr. Syed Rehan of PAKISTAN (in burgandy shirt). Dinner was hosted by KD Medical's John Powers (gray shirt) in Las Vegas, NV, original home of our parent, public company Calbatech (now in San Diego, CA)
[url]http://www.kdmedical.com/frontend/news_detail.asp?id=432369445[/url
Posted by QuestSolver on :
as some on the other board stated.....since the Medspa's are a big thing for many and since Hollywood is one of the locations it would surely be nice to see some Celeb's getting this done!!!
maybe even Arnold!!!
Posted by QuestSolver on :
for the hell of it I e-mailed paul and also called the company concerning the celeb's angle...heres what I sent and also left the same message on CalbaTechs line at 949-450-9910....LOL...that would be great publicity and maybe a few of you would like to call them and give some opinions.
Paul
You may think this is going out on a limb but have you or the company considered contacting the Governor of CA (Arnold)? Since he is pro stem cell research do you think he would consider getting the banking done? Hell give it to him free of charge because the publicity would be phenomenal!! maybe even some other celebs to!
I always feel good when I see JimSC posting. Posted by QuestSolver on :
got a response from IR!
Hank: I'll share your suggestions with mngt.
Paul Knopick
Posted by QuestSolver on :
can you imagine how this would hit the fan if they announce that Arnold will be at their Med Spas for his first stem cell extraction!!! this stock would hit the dollars quick!!
Posted by QuestSolver on :
I just e-mailed the Gov!! also sent him the last PR by CLBE concerning the opening of the stem cell banking system and ask if he would consider it since he is a health advocate and supports stem cell technology!
CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on banking adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech, pharmaceutical research market and to academic institutions, announced today that its wholly owned subsidiary, LifeStem, Inc. will begin operations of its Adult Stem Cell Microbank(TM) collection service on August 15th 2006.
LifeStem's Stem Cell Microbank(TM) Service is the nation's first service to collect micro quantities of adult stem cells from multiple tissue sources. "We have completed the validation of our protocols to guarantee that our service will run smoothly at the time of launch," said James DeOlden, CEO. "LifeStem and its partners are now satisfied with the vitality and viability of the cells that have been collected."
A number of individuals have already expressed interest in being the first to store their stem cells with LifeStem once the Service has begun. The company will begin enrolling clients immediately. LifeStem will also begin its marketing efforts immediately to take advantage of the time between today's date and the 15th of August to schedule other individual's stem cell harvests.
Additionally, CalbaTech, in coordination with LifeStem, announced that it will be offering a ten percent discount coupon for LifeStem's Stem Cell Microbank(TM) collection service, to shareholders of record as of August 10, 2006. The discount is available to the individual shareholder, or any member of the shareholder's immediate family at the shareholder's listed address.
CalbaTech's wholly owned subsidiary LifeStem has developed a unique process to harvest stem cells from two tissue sources, in micro quantities, to be cryopreserved for possible future therapeutic use. The collection of stem cells from two different tissue sources increases the potential for possible treatment options of more diseases.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Posted by QuestSolver on :
I also contacted Governor Ehrlich of Maryland,he's a strong advocate of stem cell research and has already set it in the budget for funding.
Posted by QuestSolver on :
Schwarzenegger Discusses Executive Action to Strengthen Stem Cell Research in Press Conference Friday GOVERNOR SCHWARZENEGGER:
Good morning, everybody. Good morning. Yesterday I directed my Department of Finance to loan up to 150 million dollars to the California Institute for Regenerative Medicine. The court’s affirmative decision a few months ago in the Proposition 71 challenge leads me to believe that there’s no reason why we should not go and make this money available as soon as possible. I’m 100 percent committed to advancing stem cell research in California, and to the promise that it holds for millions of our citizens who suffer from chronic diseases. California is poised to lead not only the state but the country, and all countries, on stem cell research. We cannot fall behind other nations that make this life-saving science their priority. I believe it is critical that we take action to ensure continued progress of this revolutionary science. This is another opportunity of the people of California to lead the way.
Thank you. And now I would like to have my friend Bob Klein, who is actually the man that has led Proposition 71 to victory, come out and say a few words. Please.
Posted by QuestSolver on :
should start to see a volume increase soon based on tomorrows openings and projected quarterly.
Posted by QuestSolver on :
looks like Barchart made some changes in our favor
Composite Indicator -- Signal -- -- Strength -- -- Direction -- Trend Spotter (TM) Hold Bullish
Short Term Indicators 7 Day Average Directional Indicator Buy Minimum Strengthening 10 - 8 Day Moving Average Hilo Channel Buy Minimum Weakening 20 Day Moving Average vs Price Buy Minimum Strongest 20 - 50 Day MACD Oscillator Buy Average Weakest 20 Day Bollinger Bands Hold Bullish
Short Term Indicators Average: 80% - Buy
Medium Term Indicators 40 Day Commodity Channel Index Hold Bullish 50 Day Moving Average vs Price Buy Weak Strongest 20 - 100 Day MACD Oscillator Buy Minimum Weakening 50 Day Parabolic Time/Price Buy Average Strongest
Medium Term Indicators Average: 75% - Buy
Long Term Indicators 60 Day Commodity Channel Index Hold Rising 100 Day Moving Average vs Price Buy Minimum Strongest 50 - 100 Day MACD Oscillator Sell Minimum Weakest
Long Term Indicators Average: - Hold
Overall Average: 56% - Buy Posted by QuestSolver on :
if we get a positve 10-Q after hours this will surely gap hard in the AM
Posted by QuestSolver on :
Originally Posted by miagiovni e mail sent from another board: Email-Sent to Governor Arnold....Ca. The Governor, Arnold, A company that stores stem cells,located in Irvine California Name...Calbatech,Inc. Would it not be great to show your belief in the research and storage. By having you the first Governors of our USA, state.Be the first to store his adult stem cell,with the world media looking on.
Make everyone in our country a believer in the research..
This is already being done and approved in Europe, Lets not loose our good researchers to Europe,or other continents. Keep the in the USA.
Governor Arnold Be bold, and Be THE FIRST..!!! Thank You,
Posted by MotorCityMadman on :
10QSB is out...
Posted by QuestSolver on :
already like this!! no change in the OS
As of June 30, 2006, the Company had 95,918,110 shares of common stock issued and outstanding.
Posted by QuestSolver on :
PATENTS AND PROPRIETARY TECHNOLOGY
It is the Company's intention to protect its proprietary property through the filing of U.S. and international patent applications, both broad and specific, where necessary and reasonable. The Company believes it will attain strong and broad patent protection for its technologies. It is the Company's intention that all its products be protected under various pending patents, issued patents, copyrights and trademarks.
The Company has the policy of disclosing its proprietary information only under a Confidentiality Agreement. This Agreement has a special clause regarding ownership by the Company of all inventions related to, or based in any way upon, the Company's technologies.
Posted by QuestSolver on :
Management of Growth
The Company expects to experience growth in the number of employees relative to its current levels of employment and the scope of its operations. In particular, the Company may need to hire scientists, as well as sales, marketing and administrative personnel. Additionally, acquisitions could result in an increase in employee headcount and business activity. Such activities could result in increased responsibilities for management. The Company believes that its ability to attract, train, and retain qualified technical, sales, marketing, and management personnel, will be a critical factor to its future success. During strong business cycles, the Company may experience difficulty in filling its needs for qualified personnel.
Posted by QuestSolver on :
Dependence Upon Management
Our future performance and success are dependant upon the efforts and abilities of our Management. To a very significant degree, we are dependent upon the continued services of James DeOlden, Edward Deese and John Gordon, our founders and Directors. If we lost the services of Mr. DeOlden, Mr. Deese or Dr. Gordon or other key employees before we could get a qualified replacement, that loss could materially adversely affect our business. We currently maintain key man life insurance on the lives of Mr. DeOlden and Mr. Deese in the amounts of $3,000,000 and $2,842,000 respectively.
Posted by QuestSolver on :
the 10-Q is fair and shows absolutley no dilution from previous quarter which is great.The stem cell banking revs will be in Q-3 of course but as the CEO stated,CLBE will be profitable in 06 and they are surely on track. I figure we get a PR early tomorrow on the opening of the stem cell banking system.
one thing everyone can say...CLBE surely came thru and filed on time!!
Posted by QuestSolver on :
FINANCIAL PROJECTIONS
LifeStem anticipates launching its Stem Cell MircoBank Service on August 15th, 2006. LifeStem has initially concentrated on medspa locations in Southern California. At a recent meeting of all of the current Solana Medspas, a large number of the medspas outside of California expressed enthusiasm as to being able to carry LifeStem's service outside of California and LifeStem is working to make that happen more rapidly than originally anticipated. As such, the Stem Cell MicroBank Service will be initially rolled out in California and then quickly move to other states such as Florida, New York and North Carolina. LifeStem is projecting $3,858,000 in revenues in the first twelve months of operation and $26,275,000 during the second twelve months of operation. Posted by QuestSolver on :
this now shows that this company mean business and every segment compliments each other.I will surely hold a core position here for quite a while,the long term value imo will definitely be in the dollars.
Posted by atleast on :
quote:Originally posted by QuestSolver: FINANCIAL PROJECTIONS
LifeStem anticipates launching its Stem Cell MircoBank Service on August 15th, 2006. LifeStem has initially concentrated on medspa locations in Southern California. At a recent meeting of all of the current Solana Medspas, a large number of the medspas outside of California expressed enthusiasm as to being able to carry LifeStem's service outside of California and LifeStem is working to make that happen more rapidly than originally anticipated. As such, the Stem Cell MicroBank Service will be initially rolled out in California and then quickly move to other states such as Florida, New York and North Carolina. LifeStem is projecting $3,858,000 in revenues in the first twelve months of operation and $26,275,000 during the second twelve months of operation.
and your estimate of PPS based on these numbers is ...
Posted by QuestSolver on :
considering how many microbank openings are expected before year end not to mention the ones Calbatech is in partnerships with such as Solena I still believe the PPS could close the year out at or near .50's or even higher.Watch for news sometime today on the opening of the fist in CA.
Posted by QuestSolver on :
CORPORATE MISSION AND OBJECTIVES In order to accomplish its goals, CalbaTech is pursuing a strategy of combining products and technologies, and the companies that provide them, into the following divisions: 1) Molecular Applications; 2) Research Reagents; and 3) Cellular Therapeutics. By pursuing such a strategy, each division should produce value added and increasing returns on shareholders' investment through cross marketing of products and geographic expansion, as well as to achieve product enhancement and efficiency KD MEDICAL, INC. CalbaTech acquired KD in the last quarter of 2004. This acquisition substantially increased both product range and revenue in the Research Reagents Division. The product ranges of KD and Molecula are highly complementary, with little over lap. A strength of KD is in the supply of specialized media for culture of model research organisms such as bacteria, yeast, insects and mammalian cell lines. It also supplies products to approximately 300 National Institutes of Health ("NIH") laboratories, contracts invaluable for establishing new products in a favorable government setting. Its secondary products are related to molecular biology reagents. Conversely, Molecula's primary focus is in the design and supply of high value molecular biology reagents such as siRNA and DNA antisense oligonucleotides. It also has reagents such as IPTG that are complementary to customized media. KD believes that the addition of new product lines could significantly increase its revenues within the NIH, to as much as $5 Million annually, within the next five years. A large proportion of molecular biology research depends upon culture of a model organism (bacteria, fruit fly, etc.), which is genetically manipulated by transfection of customized oligonucleotides (siRNA). Thus, an alliance of KD and Molecula will be well placed to provide a competitive single source for these culture media transfection reagents and specialized modifier molecules such as siRNA. Further, as explained above, KD's long standing and trusted position, as a major in-house supplier to NIH will greatly ease entry of Molecula's siRNA into that major market. Please see www.kdmedical.com. CUSTOMERS KD Medical and Molecula service five distinct customer types: 1) Federally funded research centers such as the National Institutes of Health, the Naval Medical Center, and the National Cancer Institute; 2)Federally funded "Supply Stores" such as at the National Institutes of Health; 3) University and private research centers such as Glaxo Smith-Kline, Johnson & Johnson, Merck & Co., Pfizer Research, and Wyeth Pharmaceuticals; 4) Medical distributors such as Fisher Scientific and VWR International; and 5) OEMs such as Genetix, Ltd. and PML Microbiologicals, Inc. MARKET SIZE The general laboratory supplies industry is 12 to $14 Billion, and the molecular biology market to which the Company provides products and services for medical research and drug discovery on which billions of dollars are spent each year. Specifically, the molecular biology market is approximately $600 Million per year, and the RNAi market is estimated to be $328 Million by 2010. FINANCIAL PROJECTIONS The Reagents Division has two companies with combined 2005 revenues of approximately $1.225 Million in gross revenues. CalbaTech believes that combined revenues within the division will be $1.5 Million in 2006. Within three years, it is anticipated that revenues will grow to $5 Million. PATENTS AND PROPRIETARY TECHNOLOGY It is the Company's intention to protect its proprietary property through the filing of U.S. and international patent applications, both broad and specific, where necessary and reasonable. The Company believes it will attain strong and broad patent protection for its technologies. It is the Company's intention that all its products be protected under various pending patents, issued patents, copyrights and trademarks. The Company has the policy of disclosing its proprietary information only under a Confidentiality Agreement. This Agreement has a special clause regarding ownership by the Company of all inventions related to, or based in any way upon, the Company's technologies.
Posted by Livinonklendathu on :
CalbaTech Announces Six Month Revenues; LifeStem, Initially in California, Expects to Launch Service in Florida, New York, North Carolina and Other States in the Near Term 8/15/2006
IRVINE, Calif., Aug 15, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com ) concentrating on providing products and platforms to the biotech and pharmaceutical research market and to academic institutions, and banking of adult stem cells for possible future therapeutic uses, today announced its second quarter financial results.
Revenues for the first six months of 2006 totaled $655,122, up five percent from the same period in 2005. Revenues were down slightly in the second quarter, dropping from $310,525 in 2005 to $242,558 in 2006 because of down time while the Company moved two subsidiaries into a new facility. Gross profit increased and totaled $205,377 in the second quarter of 2006 compared to $129,665 in 2005. Accounting for derivative liability recognition caused the company to achieve net revenues of approximately $13,000 for the six-month period, as compared to a loss of approximately $2.2 million for the same period in 2005.
The Company also announced that LifeStem, its wholly owned subsidiary, presented its Stem Cell MicroBank(TM) Service at a national convention of medspa owners and anticipates launching its MicroBank(TM) Service in Florida, New York, North Carolina and other states soon after the August 15th, 2006, California launch date. LifeStem is projecting $3.9 million in revenues in the first twelve months of operating the nation's first service to collect micro-quantities of adult stem cells from multiple tissue sources for future potential therapeutic use.
James DeOlden, CalbaTech CEO, said the Company anticipates that revenues will increase throughout the balance of 2006, not only due to launching LifeStem's Stem Cell Microbank(TM) Collection Service, but also due to two subsidiaries, Molecula, Inc. and KD Medical, Inc., having combined operations to be more efficient and having moved into a new facility that should increase quality and improve manufacturing capabilities.
Posted by QuestSolver on :
yes but DT's are creatures of habit and pretty much always sell on the financials whether they are good or not the first hour of today is going to be a roller coaster ride so I advise to just sit back and watch it
Posted by maxdog on :
I really thought this would be a good day for us, not starting out so great.
Posted by QuestSolver on :
more news!!
The Nation’s First Medical Spa to Harvest Adult Stem Cells
Solana MedSpas, the nation’s foremost developer and syndicator of medical spas, has signed an agreement with LifeStem, Inc. to offer their unique Stem Cell MicroBank Service through the Solana MedSpas network. The announcement was made by John Buckingham, CEO and co-founder of Irvine, Calif.- based Solana MedSpas. LifeStem, Inc. is a wholly owned subsidiary of CalbaTech, Inc. (OTC Bulletin Board: CLBE), a publicly traded emerging life sciences company concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
“We are delighted to finalize our partnership with LifeStem,” Buckingham says, noting that Solana MedSpas will be the first medspa network to offer an adult stem cell collection service. “As Solana MedSpas continues to orchestrate the marriage of healthcare product innovation with our ever expanding medspa distribution channel, we are moving beyond aesthetic treatments to become a provider of medical services in a broader sense.” Solana MedSpas expects to have as many as 70 locations open by the end of 2006 and intends to offer the Stem Cell Microbank Service at key locations.
“We are extremely pleased that we have formalized an agreement with Solana MedSpas,” says LifeStem president Dan Fulkerson, “and are confident that many individuals within the Solana MedSpas client base will take advantage of our Stem Cell MicroBank™ service.” “By beginning with six locations and adding new outlets as Solana MedSpas debuts them, our conservative estimates project revenues in excess of $3 million over the first 12 months of operations with the potential to exceed $25 million in the next couple of years,” Fulkerson notes.
Recent research indicates that autologous (one’s own) adult stem cells provide advantages similar to embryonic stem cells without ethical controversy or the risk of rejection. Current scientific data supports the fact that adult stem cells hold the potential for treatment, cure and possible prevention of numerous afflictions such as heart disease, Parkinson’s Disease, diabetes, Alzheimer’s disease, and spinal cord injuries. Other possible benefits include regeneration of cardiac tissue after heart attack, regeneration of joint surfaces to reverse the ravages of osteoarthritis and joint disease, augmentation of the body’s ability to heal after elective surgeries to improve healing and speed recovery, and boosting of the immune system’s ability to fight infection and even cancer.
About Solana MedSpas Founded in July 2003, Solana MedSpas is the nation’s innovative leader in the development and syndication of medical spas. Solana MedSpas has created a new market segment by orchestrating the marriage of healthcare innovation with its ever expanding medspa distribution channel, making its proprietary content simultaneously available to its growing distribution network of uniquely branded medical spa facilities all over North America. Moving beyond aesthetic medical treatments, Solana MedSpas is the nation’s first medspa network to offer a broader range of medical treatments in a retail spa environment. Solana Medspas provides the industry's only model for a legally compliant, competitive, and forward-thinking business in all 50 states.
About LifeStem LifeStem, Inc. a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of “Cellular Logistics.” The Company’s focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications, and clinical applications of specific stem cell based therapies. LifeStem, in addition to being the first company to offer micro collection of stem cells,is also the first company to offer a collection service that collects and stores two different types of stem cells. The Company has filed patent applications for an endoscopic stem cell delivery device and its novel Stem Cell MicroBank service.
About CalbaTech CalbaTech, Inc. (OTC Bulletin Board: CLBE ) is an emerging life sciences company, concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
Posted by maxdog on :
Great! That should push this along.
Posted by QuestSolver on :
LifeStem, in addition to being the first company to offer micro collection of stem cells,is also the first company to offer a collection service that collects and stores two different types of stem cells. The Company has filed patent applications for an endoscopic stem cell delivery device and its novel Stem Cell MicroBank service.
Posted by Squire38 on :
quote:Originally posted by maxdog: I really thought this would be a good day for us, not starting out so great.
It seems the last few big runs I have been in, the MMs hold it down and even drop it after good news. They collect a lot of shares are people sell. Then the next day or two they run the crap out of it. See IGAI for an example. The 10Q came out the PPS dropped. Then next day it dropped big time to 0.0034, then 3rd day BOOM to almost 6 cents.
I'm not saying it will have an IGAI run, but it just seems thats what the MMs are doing these days.
Posted by QuestSolver on :
.055 and .058 on that last buy....I sill think this closes green today
Posted by QuestSolver on :
this is a company right on track that they didn't even need to increase the OS in 2 quarters and thats still under 100 mill with 25% of those locked up by insiders....so that tells me they are pretty much self supportive right now.
Posted by QuestSolver on :
.057 and .058
Posted by maxdog on :
Squire, I certainly hope your correct, a nice little run is in order now after this close.
Posted by Grico on :
up 22% today
Posted by maxdog on :
A good opportunity to buy, I can't imagine it staying this low for long
Posted by maxdog on :
Anyone still out there, thoughts?
Posted by insuranceman on :
It keeps on doing this, going up just a bit, and then dropping back down. I am still negative for when I bought three weeks ago. Its been "next week" for about a month.
Posted by GlassCrasher on :
I am very red on this one, but it does have alot of potential if you look at the long term.
Posted by maxdog on :
I guess I am long term then, because I am a nice shade of red as well
Posted by GlassCrasher on :
Good buying opportunity today in the mid .04's.
Posted by GlassCrasher on :
ARCA just came in with a large bid at .048
Posted by maxdog on :
So Quest, are you still in this thing?
Posted by insuranceman on :
All those posts by Quest, now nothing since thee 15th. Interesting.
Posted by Squire38 on :
I don't know about Quest, but I am continuing to buy. Trying to get more under $0.045. Hopefully $0.04 before the MMs run it.
Posted by insuranceman on :
Why would they do that when they had thier chance with all the PR recently.
Posted by atleast on :
CalbaTech Highlights Positive Report in Cell Online Magazine - Research Provides New Data That Further Supports Adult Stem Cell Banking Service IRVINE, Calif., Aug. 21 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com ) concentrating on providing products and platforms to the biotech and pharmaceutical research market and to academic institutions, and banking of adult stem cells for possible future therapeutic uses, today announced that a recent research report provides new data that initially suggests that cells collected during the Stem Cell MicroBank(TM) Service can be manipulated to mirror embryonic stem cells. The link to the article is http://www.cell.com/content/article/fulltext?uid=PIIS0092867406009767.
Much of the controversy surrounding embryonic stem cells centers on the destruction of the embryo caused during the harvesting of the stem cells. Researchers have largely focused their attention on embryonic stem cells due to the cell's plasticity or the ability of stem cells to differentiate into specialized cells of another tissue type. Advancements in therapies to date have been made because of the amount of resources provided to embryonic stem cell research.
This report, however, may signal a shift in focus by researchers as the plasticity in adult stem cells is better understood. Using autologous stem cells at the time of transplantation might also overcome a major unknown hurdle related to embryonic stem cells, that being possible tissue rejection. Proponents of embryonic stem cell research rarely discuss this potential limitation, while the transplantation of autologous adult stem cells should not result in tissue rejection.
CalbaTech's wholly-owned subsidiary, LifeStem has created a multi-tissue, autologous adult stem cell banking service that allows adults to bank their own stem cells for possible future therapeutic use.
LifeStem's Chief Medical Officer, Dr. Jason R. Van Tassel noted that in this study, the cells were generated from adult cultured fibroblasts under specific conditions whereby the cells were grown in the presence of several transcription factors expressed by embryonic stem cells. These cells were then implanted into both mouse embryos and adult mice and differentiated into the three cell lineages seen in early development. This could be the 'holy grail' for autologous banking of adult stem cells.
'Further in-vitro directed differentiation of these induced stem cells to specific cell types could provide a limitless source of a variety differentiated cells for numerous human therapeutic applications. We are entirely encouraged by this new data and we believe that it brings new concrete evidence that autologous adult stem cell banking is the proper strategy for patients to benefit from this emerging field,' said Dr. Van Tassel. The study did show, however, that when these induced stem cells were transplanted into adult mice, several mice developed tumors. Dr. Van Tassel continued, 'This is to be expected in a preliminary study where such highly undifferentiated cells were implanted. Furthermore, subsequent differentiation of these populations should eliminate the risk of malignancy in therapeutic applications.'
LifeStem, Inc. has launched its Stem Cell MicroBank(TM) Service in California and expects to add Florida, New York, North Carolina and other states in the very near future. LifeStem is projecting $3.9 million in revenues in the first twelve months of operating the nation's first service to collect micro-quantities of adult stem cells from multiple tissue sources for future potential therapeutic use.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain 'forward-looking' information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. We use words such as 'anticipate,' 'believe,' 'expect,' 'future,' 'intend,' 'plan,' and similar expressions to identify forward-looking statements. These statements including those related to being in a large and growing market, exhibiting rapid growth characteristics, and having a growth strategy, are forward looking statements. These forward looking statements are only predictions and are subject to certain risks, uncertainties and assumptions. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or assumptions in this press release include the risk that we will not be able to grow our revenues and market share, the risk that our prices do not remain competitive and the risk that we will not achieve profitability. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission, including our most recent Report on Form 10-KSB, and Reports on Form 10-QSB and Form 8-K. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
I saw that. Its actually a link under the sign on cnnfn
Posted by Rbreb13 on :
quote:Originally posted by insuranceman: All those posts by Quest, now nothing since thee 15th. Interesting.
He had some family matters to attend to. Be assured, he's still very much in this one. As am I.
Posted by Squire38 on :
quote:Originally posted by insuranceman: Why would they do that when they had thier chance with all the PR recently.
Review IGAI's 1300% run. Psychologically a PR comes out, everyone assumes it will run. So the MMs actually lower the PPs, people bail, MMs collect cheap shares, then they run it when they are ready. They, of course win.
Posted by insuranceman on :
Okay then. Thanks for the info guys.
Posted by insuranceman on :
I looked at that IGAI. Thats crazy. Its now back down, which would be bad in the long run.
Posted by Squire38 on :
quote:Originally posted by insuranceman: ...which would be bad in the long run.
These are penny stocks, never care about the long run. Use them, get your profit and get out.
Posted by insuranceman on :
Advice duely taken Squire. I am still learning.
Posted by Repoman75 on :
This is going to fly tomorrow based on ACTC momo... I'm in at .06.
![[Big Grin]](biggrin.gif)
![[Smile]](smile.gif)